Walvax subsidiary gains Jordan vaccine approval, patent for vial cleaning tech

Walvax Biotechnology announced that its subsidiary, Yunnan Walvax Biotechnology Co., Ltd., has received a drug registration certificate from the Jordan Food & Drug Administration for its 13-valent pneumococcal polysaccharide conjugate vaccine. This vaccine, approved for infants and children aged 6 weeks to 5 years, prevents infectious diseases caused by 13 serotypes of pneumococcus and was first approved in China in 2020. The Jordanian approval marks a crucial step in Walvax's Middle East market strategy, noting that pneumococcal infections are a leading cause of death for children under five globally.

The company also announced the receipt of an invention patent certificate from China's National Intellectual Property Administration for integrated vaccine vial cleaning, disinfection, and drying equipment. This patented technology enhances cleaning efficiency and drying effectiveness for vaccine vials. The patent, jointly owned by Walvax Biotechnology and Yunnan Vaccine Laboratory Co., Ltd., is valid for 20 years from its application date of December 24, 2024.

This invention patent is already being applied in Walvax's product and project R&D, strengthening its intellectual property protection and core competitiveness. While the patent is not expected to significantly impact this year's operating results, the Jordanian drug registration represents a key international expansion for the company's vaccine portfolio.